Consort Targets Complete Drug Delivery Service, But Rivals Keep Heat On
Executive Summary
Industry activity in the drug delivery device sector is characterized more by stability than speed. Consort Medical's recent strategic moves have been both deliberate and decisive. For these players, deals with pharma can be several years in the making.
You may also be interested in...
Pivotal Opportunity For UK Medtech Must Not Be Wasted
The UK continues to work on its new medtech regulatory system and market access processes for innovations, but all the planning and preparations will count for little if not accompanied by sound execution, warns Lincoln Tsang of law firm Ropes & Gray.
EU MDR Extended Transitions: Practical Advice From Commission
Concerns and uncertainties arising among manufacturers following the recent extension of the MDR's transition periods have been addressed in a question-and-answer document issued by the European Commission.
Take Timely Steps To Alleviate Upcoming IVDR Compliance Woes
The transition periods for complying with the EU’s In Vitro diagnostics medical devices regulation might have been extended, but that does not change the scale of the compliance task at hand for manufacturers, says digital labeling provider Kallik.